Frank Rimerman Advisors LLC Has $273,000 Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Frank Rimerman Advisors LLC lifted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,490 shares of the company’s stock after purchasing an additional 265 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in GE HealthCare Technologies were worth $273,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth $31,000. Continuum Advisory LLC grew its holdings in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. Bank of Jackson Hole Trust acquired a new stake in shares of GE HealthCare Technologies during the 4th quarter worth $32,000. OFI Invest Asset Management acquired a new stake in shares of GE HealthCare Technologies during the 4th quarter worth $34,000. Finally, Avion Wealth boosted its stake in GE HealthCare Technologies by 497.4% in the fourth quarter. Avion Wealth now owns 460 shares of the company’s stock valued at $35,000 after buying an additional 383 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance

Shares of GEHC stock opened at $82.47 on Tuesday. The business’s 50-day moving average price is $87.27 and its 200-day moving average price is $86.12. GE HealthCare Technologies Inc. has a 12 month low of $74.51 and a 12 month high of $94.80. The firm has a market capitalization of $37.71 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 3.19 and a beta of 1.13. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. Equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Wells Fargo & Company raised their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Citigroup raised their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $100.00 in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and an average target price of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.